Researchers Gain Faster Access to Complex DNA as Integrated DNA Technologies and Ansa Biotechnologies Expand Ordering Platform
Streamlined workflow provides earlier visibility into synthesis feasibility, pricing, and fulfillment options.
News & Events
Webinar: Codon Optimization Isn’t Equal – Benchmarking Gene Design for Antibody Expression
In this GEN webinar, Justin Byers and Daniel Lin-Arlow, PhD, examine how enzymatic DNA synthesis and DNA construct design mitigate antibody expression challenges. Register here.
Ansa Biotechnologies to Showcase Breakthrough DNA Synthesis Technology Backed by Industry’s Only On-Time Guarantee at SynBioBeta 2026 Conference
Direct, sequence-perfect clonal DNA up to 50 kb is empowering customers to expand their design space and innovate without compromise.
Ansa Biotechnologies Appoints Matthias Arenskötter as Chief Operating Officer
Seasoned DNA synthesis executive will oversee expansion of production capacity to meet rising demand for high-quality long and complex DNA products backed by industry’s only service guarantee.
Integrated DNA Technologies Expands Synthetic Biology Portfolio with Ansa Biotechnologies’ Clonal DNA and XL Clonal DNA Products
New collaboration empowers customers with sequence-perfect constructs as long as 50 kb.
Ansa Biotechnologies Targets Nucleic Acid Synthesis Market With Ultra-Long Clonal DNA Service
Enzymatic DNA synthesis company Ansa Biotechnologies hopes to win a slice of the nucleic acid synthesis market with ultra-long DNA products that it believes are hard to obtain with traditional phosphoramidite-based chemical synthesis.
Ending The Waiting Game: How Ansa Biotechnologies Guarantees are Turning DNA Synthesis Into A Predictable Industry
When Jason T. Gammack talks about DNA synthesis, he does not start with base chemistry or instrument design. He starts with broken promises. For decades, synthetic biology teams have designed pathways in hours, then waited weeks or months for gene fragments that arrived late, arrived wrong, or never arrived at all. Read the full article from SynBioBeta.
Ansa Biotechnologies Appoints Geoff Hamilton as Chief Financial Officer and Chief Business Officer
Mr. Hamilton will lead the company’s financial operations, corporate strategy, and key partnerships as Ansa accelerates its commercial expansion across the biotechnology, synthetic biology, and pharmaceutical sectors.
Webinar: Revolutionizing Gene Therapies through Rapid, Large DNA Synthesis & Designable Delivery Vehicles
In this joint webinar, EndoFold, Inc. and Ansa Biotechnologies share results from a proof-of-concept collaboration demonstrating a new path forward: ultra-rapid synthesis of full-length therapeutic constructs paired with next-generation, designable delivery vehicles.
Ansa Biotechnologies Redefines What’s Possible in DNA Synthesis with 50 kb Sequence-Perfect Clonal Product
Ansa is the first to deliver ultra-long, fully verified DNA in less than 25 days, backed by the industry’s only on-time guarantee. View the press release.